Mark Posner, MD
Allergy & Immunology · Blue Bell, PANPI 1508869637
Payments from drug & device makers
Across 515 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$865
- CSL Behring$769
- Pfizer$658
- plus $4K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,264 |
| Sanofi | 57 | $1,247 |
| GSK | 53 | $1,098 |
| Regeneron Healthcare Solutions, Inc. | 27 | $865 |
| CSL Behring | 37 | $769 |
| Pfizer | 45 | $658 |
| Kaleo, Inc. | 33 | $625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $595 |
| Genentech USA, Inc. | 20 | $456 |
| Alk-abello, Inc | 9 | $283 |
| Amgen(2 entities) | 7 | $241 |
| Biocryst US Sales Co., LLC | 10 | $226 |
| Blueprint Medicines Corporation | 6 | $218 |
| Grifols USA, LLC | 9 | $172 |
| Covis Pharma GmbH | 9 | $135 |
| Bio Products Laboratory USA, Inc. | 9 | $132 |
| Octapharma USA, Inc. | 6 | $122 |
| Boehringer Ingelheim | 6 | $121 |
| Optinose US, Inc. | 7 | $115 |
| Sanofi-aventis U.S. LLC | 2 | $115 |
| Shire North American Group Inc | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Novartis | 3 | $50 |
| AbbVie | 3 | $49 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
| Organon | 3 | $41 |
| Merck | 2 | $28 |
| Verona Pharma, Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| LEO Pharma Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $13 |
How this compares
$10,920 in reported general payments places this provider in the 70th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other allergy & immunology in Blue Bell
- Robert AnolikBlue Bell$159K
- David KrauseBlue Bell$14K
- Anjana KhuntiaBlue Bell$9K
- Patrick VannelliBlue Bell$7K
- Matthew FoggBlue Bell$7K
- Drew WeissmanPhiladelphia$15.3M
- Timothy CraigHershey$2M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Sandra GawchikUpland$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.